Alex Eggermont, general director of the Institut de Cancérologie Gustave Roussy, is one of five experts to be appointed to a new advisory board at ISA Pharmaceuticals BV in the Netherlands. ISA is developing therapeutic vaccines against cancer and viral infections. Dr Eggermont is also a professor of surgical oncology at Erasmus University in Rotterdam.
The other board members are: Ulrich Granzer, a pharmacist and founder of Granzer Regulatory Consulting & Services in Germany; Drew Pardoll, a cancer immunologist and professor of oncology at Johns Hopkins University School of Medicine in the US; Sjoerd van der Burg, a professor in experimental cancer immunology and therapy at the Leiden University Medical Center in the Netherlands; and Mark Krul, a co-founder of ISA and co-founder and managing partner at Aglaia BioMedical Ventures in the Netherlands.
ISA Pharmaceuticals announced the appointments on 15 October 2013.
Copyright 2013 Evernow Publishing Ltd